Telix at EANM 2025

Join Telix at EANM in Barcelona, to learn more about how we are delivering on the promise of precision medicine through targeted radiation.

The program features a record 28 company-related abstract presentations, showcasing our late-stage and next generation development programs and innovations in MedTech.

On Sunday 5th October at 13:15 in room 116, Telix will bring together expert speakers to discuss the journey “From Pan-Tumor Innovation to Theranostic Precision – FAP and CAIX Case Studies“.

The sponsored symposium will be chaired by Prof. Antoine Italiano, with presentations from Dr. Yuriko Mori, Prof. Dr. Richard P Baum, Prof. Dr. Daniela Oprea-Lager and Dr. Christina Suárez.

Visit booth #78 to explore opportunities for collaboration with Illuccix® (kit for the preparation of gallium-68 gozetotide injection) Telix’s commercial PSMA-PET imaging agent in Europe, our industry-leading theranostic pipeline and medical technologies, including the SENSEI® miniature drop-in gamma probe, QDOSE® dosimetry software and artificial intelligence (AI).

Barcelona International Convention Center​
Plaça de Willy Brandt, 11-14, ​
Sant Martí, 08019 Barcelona, Spain
4th-8th October, 2025

View full congress programme here

Your subscription could not be saved. Please try again.
Your subscription has been successful.

To hear more from Telix on their commitment to the European nuclear medicine community, sign up below


5 October 2025
Oral presentations
6 October 2025
Oral presentations
7 October 2025
Oral presentations
8 October 2025
Oral presentations
Poster Presentations
e-Poster Area
Rhine Pharma presentations
Oral and poster presentations
5 October 2025
Oral presentations
Investigating FAP binding of the dimeric DOTAGA.Glu.(FAPI)2 (TLX400) labelled with terbium-161 in ovarian cancer models incorporating the tumor microenvironment*
5-Oct-25, 15:10 – 15:20

Presenter: I. Primac, SCK CEN, Mol, Belgium

Abstract #: OP-150

6 October 2025
Oral presentations
Reactive evaluation – a novel alternative to transfer learning to handle multi-centric variations in prostate cancer cohorts
6-Oct-25, 09:45 – 09:55

Presenter: L. Papp, Medical University of Vienna, Vienna, Austria

Abstract #: OP-352

Tumor-stroma dynamics define FAP optimum imaging and therapeutic windows in the management of glioblastoma*
6-Oct-25, 16:00 – 16:10

Presenter: A. Bilinska, Bern University Hospital, Bern, Switzerland

Abstract #: OP-417

7 October 2025
Oral presentations
Synergistic anti-tumor effects of 225Ac-DOTA-girentuximab (TLX252) combined with DNA damage response inhibitors in CAIX-positive renal cancer
7-Oct-25, 08:10 – 08:20

Presenter: Z. Cao, Olivia Newton-John Cancer Research Institute and Austin Health, Heidelberg, Australia

Abstract #: OP-516

Integration of spatial analysis and deep learning for enhanced tumor classification in total-body PET/CT imaging: a preliminary study
7-Oct-25, 08:50 – 09:00

Presenter: D. Han, Telix Pharmaceuticals, Sydney, Australia

Abstract #: OP-529

Combining CAIX-targeted radionuclide therapy with immune checkpoint inhibitors: which inhibitor and when?
7-Oct-25, 09:00 – 09:10

Presenter: S. Kleinendorst, RadboudUMC, Nijmegen, Netherlands

Abstract #: OP-521

ProstACT Global: A Phase 3 study of lutetium (Lu177) rosopatamab tetraxetan (TLX591) plus standard of care vs standard of care alone in patients with metastatic castration-resistant prostate cancer
7-Oct-25, 15:40 – 15:50

Presenter: J. Piulats, Bellvitge Biomedical Research Institute, Barcelona, Spain

Abstract #: OP-674

Preliminary assessment of 89Zr-Girentuximab (TLX250-CDx) excretion and radiation protection in ccRCC patients undergoing PET/CT imaging
7-Oct-25, 17:35 – 17:45

Presenter: A. Piai, IRCCS Ospedale San Raffaele, Milan, Italy

Abstract #: OP-706

8 October 2025
Oral presentations
IPAX-Linz: Phase 2 study to evaluate safety, tolerability, and preliminary efficacy of carrier-added 131I-IPA (TLX101) in patients with recurrent GBM concomitantly to 2nd line re-irradiation
Date and Time: 8-Oct-25, 08:00 – 08:10

Presenter: J. Pichler, Kepler University Hospital, Linz, Austria

Abstract #: OP-778

Safety of radioligand therapy with 177Lu-FAPi-Dimer (TLX400) with dose escalation in a clinical setting*
Date and Time: 8-Oct-25, 08:10 – 08:20

Presenter: J. Urena Poch, Rostock University Medical Center, Rostock, Germany

Abstract #: OP-779

Immunomodulation of the tumor microenvironment by 225Ac-DOTA-girentuximab (TLX252) in a syngeneic murine tumor mode
Date and Time: 8-Oct-25, 09:10 – 09:20

Presenter: R. Ladjohounlou, University of Wisconsin, Madison, WI, U.S.

Abstract #: OP-767

Poster Presentations
e-Poster Area
Presentations
Title: Preclinical development of 161Tb-DOTA-HYNIC-panPSMA and comparison with 177Lu-DOTA-HYNIC-panPSMA, 161Tb-DOTA-J591 and 177Lu-DOTA-J591 (TLX591)

Presenter: C. Morgat, CHU Bordeaux, Bordeaux, France

Abstract #: EP-0069

CAIX-targeting for radioimmunotherapy in triple-negative breast cancer

Presenter: A. Ivashkevich, Telix Pharmaceuticals, Melbourne, Australia

Abstract #: EP-0130

Prostate cancer detection with 99mTc-HYNIC-iPSMA SPECT: The Australian experience

Presenter: P. Tually, Spartan First Imaging, Kalgoorlie, Australia

Abstract #: EP-0353

Potential of 89Zr-girentuximab (TLX250-CDx) PET/CT for the routine clinical management of patients with suspicious, unspecified renal lesions (real-world experience)

Presenter: S. Rasul, Medical University of Vienna, Vienna, Austria

Abstract #: EP-0528

Improving clinical management of von Hippel-Lindau Syndrome with 89Zr-girentuximab (TLX250-CDx) PET Imaging (real-world experience)

Presenter: F. Gelardi, IRCCS Ospedale San Raffaele, Milan, Italy

Abstract #: EP-0534

IPAX-2: Phase 1 safety and dose finding study of 131IIPA (TLX101) plus standard of care in patients with newly diagnosed glioblastoma

Presenter: J. Pichler, Kepler University Hospital, Linz, Austria

Abstract #: EP-0785

177Lu-DOTA-HYNIC-panPSMA radioligand therapy for patients with metastatic castration-resistant prostate cancer

Presenter: Y. Omar, Misr Radiology Center, Cairo, Egypt

Abstract #: EP-0810

Robust self-supervised deep learning reconstruction model for reduced 89Zr-girentuximab (TLX250-CDx) PET scan time

Presenter: C. Pain, Monash Biomedical Imaging, Melbourne, Australia

Abstract #: EP-0978

Preclinical evaluation of DOTAGA.PEG2.Glu.(FAPI)2, a FAP dimeric inhibitor, for developing theranostic radiotracers in FAP-positive malignancies*

Presenter: N. Kumar, Bern University Hospital, Bern, Switzerland

Abstract #: EPS-013

Intraindividual tumor dosimetry of monomer 90Y-FAPI-46 vs dimer 90Y-DOTAGA-Glu-(FAPI)2 FAP radioligand therapy of advanced stage solid tumors*

Presenter: P. Fragoso Costa, University Hospital Essen, University Duisburg-Essen, Essen, Germany

Abstract #: EPS-190

Therapeutic potential of DOTAGA.Glu.(FAPI)2 (TLX400) and DO3A.Glu.(FAPI)2 with human dosimetry extrapolation for 177-lutetium and 161-terbium*

Presenter: A. Bilinska, Bern University Hospital, Bern, Switzerland

Abstract #: EPS-193

Rhine Pharma presentations
Oral and poster presentations
Impact of formulation buffers on the radiolysis and stability of RHN001-Tx (188Re-PSMA)
Date and Time: 6-Oct-25, 10:45 – 10:55

Presenter: S. Mdanda, Nuclear Medicine Research Infrastructure (NuMeRI), Pretoria, South Africa

Abstract #: OP-349

Clinical trial protocol for RHINO trial: Prospective single-center Phase 1/2 study of RHN001-Dx/Tx in men with PSMA-positive prostate cancer post adjuvant androgen deprivation therapy and/or taxane-based chemotherapy
Date and Time: 8-Oct-25, 09:20 – 09:30

Presenter: H. Ndlovu, NuMeRI, Pretoria, South Africa

Abstract #: OP-825

A comparative analysis of normal organ biodistribution and tumor uptake pattern of novel RHN001-Dx (99mTc-PSMA) in correlation with tumor burden and its implications for theranostic use
Date and Time: 8-Oct-25, 11:05 – 11:15

Presenter: S. Martlbauer, University Hospital Dusseldorf, Heinrich-Heine-University Dusseldorf, Dusseldorf, Germany

Abstract #: OP-881

A calibration workflow for accurate quantification of rhenium-188 in RHN001-Tx for theranostic applications

Presenter: M. Qebetu, NuMeRI, Pretoria, South Africa

Abstract #: EP-0942

Quantitative 99mTc-SPECT/CT dosimetry using a CZT gamma camera: Initial clinical experience

Presenter: K. Ramonaheng, NuMeRI, Pretoria, South Africa

Abstract #: EP-1116

Production optimization and quality control testing of RHN001-Tx (188Re-PSMA) per GMP standards

Presenter: S. Sibiya, NuMeRI, Pretoria, South Africa

Abstract #: EP-1200

Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Telix’s SENSEI® drop-in gamma probe is registered with the Australian Therapeutic Goods Administration (TGA) and with the FDA and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area. Telix’s QDOSE® dosimetry software has received 510(k) clearance from the FDA and is CE-marked and Medical Device Regulation (MDR) certified for clinical use within the European Union (EU). No other Telix product listed above has received a marketing authorization in any jurisdiction.

*Presentation includes information about a Telix-owned or licensed FAP-targeting theranostic candidate without input or support from Telix.